ResMed Finalizes Purchase of Inova Labs

Financial terms were not disclosed.

The deal will allow ResMed to expand its respiratory care offerings and solutions for people with chronic obstructive pulmonary disease (COPD), which currently include products such as the AirCurve 10 series of cloud-connected noninvasive ventilators, the Stellar series of noninvasive ventilators, and the Astral lightweight noninvasive life-support platform with internal and external batteries that provide up to 24 hours of freedom for patients.

The acquisition will add both portable oxygen concentrators and necessary stationary options for the home to the ResMed portfolio, which include the LifeChoice Activox, a lightweight and portable oxygen concentrator that provides enhanced battery life for greater freedom and mobility, and the Activox DUO2, a fully integrated stationary and portable oxygen concentrator system. Oxygen therapy is the largest non-drug delivery medical device segment for the treatment of COPD.

“With the acquisition of Inova Labs, ResMed is delivering on its commitment to find further ways to improve the quality of life for tens of millions of people as they deal with COPD, this chronic, progressive disease that literally takes patients’ breath away when untreated,” said Mick Farrell, CEO of ResMed. “We are excited to expand our offerings and solutions for the global COPD epidemic and to progress even more swiftly toward our ResMed goal of improving 20 million lives by 2020.”

“ResMed is the global leader in connected healthcare solutions for sleep and respiratory conditions. That’s a perfect fit with our mission to offer oxygen therapy solutions that empower individuals to stay active and sleep well,” said John Rush, CEO of Inova Labs. “We are excited about joining forces with ResMed and benefiting from their global expertise and innovative culture, to improve patient engagement and adherence to treatment, to create business efficiencies for home medical equipment providers, and to help enhance the quality of life for those suffering from COPD and other chronic respiratory conditions.”

COPD is the co-occurrence of chronic bronchitis and emphysema, a pair of commonly co-existing diseases of the lungs in which the airways become narrowed. This leads to a limitation of the flow of air to and from the lungs, causing shortness of breath (dyspnea). In clinical practice, COPD is defined by its characteristically low airflow on lung function tests. In contrast to asthma, this limitation is poorly reversible and usually gets progressively worse over time. Worldwide, COPD ranked as the sixth leading cause of death in 1990, and is projected to be the fourth leading cause of death worldwide by 2030, due to an increase in smoking rates and demographic changes in many countries.

Related Links:
ResMed
Inova Labs